The overall 5-year survival of patients with cancer of the esophagus submitted to resection is 15–34%. Most patients who undergo radical esophagectomy relapse during the course of their disease. In recent years, there has been a growing interest in neoadjuvant treatments, which have produced better results in comparison with adjuvant protocols. There is clear evidence supporting chemoradiotherapy (CRT) for cancers of the esophagus. CRT gives a high rate of complete response (CR), and some researchers have questioned the role of surgery in cases of CR. This has led to trials on definitive chemoradiotherapy (dCRT). These experiences have produced a growing indication for a very demanding procedure: salvage surgery.
Resection of esophageal cancers carries a high rate of morbidity. Efforts have been made in recent years to verify if the application of minimally invasive surgery in this field could be advantageous in reducing the rate of morbidity (especially in terms of respiratory complications). Also, in recent years, increasing numbers of patients have been selected for endoscopic treatment for early cancers.
The aim of this chapter is to give on overview on these topics (neoadjuvant and adjuvant treatment, dCRT and salvage surgery, minimally invasive surgery and endoscopic resection) in the treatment of esophageal neoplasms.
- Esophageal Cancer
- Gastric Malignancies
- Colon Cancer
- Carcinomas of the Rectum and Anu
- Hepatobiliary Cancer
- Pancreatic Adenocarcinoma
- Pancreatic Cystic Tumors
- Gastrointestinal Stromal Tumors: Surgical and Medical Therapy
- New Knowledge in the Diagnosis and Medical Treatment of Pancreatic Neuroendocrine Tumors
- Adrenal Tumors
- Hematologic Malignancies of Surgical Interest and Splenic Tumors
- What’s New in Surgery for Kidney Cancer?
- Well-Differentiated Carcinomas of the Thyroid Gland and Neoplasms of the Parathyroid Glands
- Non-invasive and Invasive Breast Cancer
- Pulmonary Malignancies
- Surgical Emergencies in Cancer Patients
- Cancers of Unknown Origin